Health technology assessment

Deakin Health Economics

Our work contributes to ensuring that only safe, effective and cost-effective medicines and medical services are publicly subsidised in Australia under their respective schemes.

The Economics of health technology assessment research stream at Deakin Health Economics works collaboratively with the Commonwealth Department of Health undertaking evaluations of:

  • medicines considered by the Pharmaceutical Benefits Advisory Committee (PBAC) that are seeking listing on the Pharmaceutical Benefits Scheme (PBS); and
  • medical services considered by the Medical Services Advisory Committee (MSAC) that are seeking listing on the Medicare Benefits Schedule (MBS)

Our work contributes to ensuring that only safe, effective and cost-effective medicines and medical services are publicly subsidised in Australia under their respective schemes.

The Economics of health technology assessment team has also undertaken post-market reviews of medicines listed on the PBS and evaluations for the Ministry of Health, New South Wales and Agency for Care Effectiveness (ACE) in Singapore.

Our Economics of health technology assessment team leader is Associate Professor Silva Zavarsek. 
Email: silva.zavarsek@deakin.edu.au

General information about the evaluations:

Although the work conducted for the PBAC and MSAC varies slightly, common requirements are:

  • assessment of the appropriateness of the proposed positioning or clinical place of the intervention/service that can be used in the management of a condition, most importantly to define appropriate comparator(s)
  • ensuring that intended use is consistent with relevant regulatory approvals
  • conducting/checking a systematic search of the literature (including ongoing trials) to ensure that reports of all studies relating to the clinical question at hand (and those that may become relevant in future) have been identified
  • conducting or checking that clinical data from published and unpublished reports of clinical studies are systematically and accurately extracted, analysed, synthesised
  • preparing/commenting on a summary conclusion in regard to the comparative effectiveness and safety
  • validating the accuracy or developing de novo models for economic evaluations. This includes the conduct of cost-minimisation analyses and full modelled economic evaluations, including decision trees, Markov cohort and microsimulation models
  • validating the accuracy or developing de novo models to estimate the financial implications when considering public subsidy. Estimates derived from epidemiological or market share approaches